Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) AI Stock Analysis

• Market Cap: HK$11.11B
• Dividend Yield: N/A
• Average Volume (3M): 332.68K
• Price to Earnings (P/E): 77.7
• Beta (1Y): 1.07
• Revenue Growth: 48.38%
• EPS Growth: N/A
• Country: HK
• Employees: 1,117
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.13
• Shares Outstanding: 110,781,920
• 10 Day Avg. Volume: 282,500
• 30 Day Avg. Volume: 332,677
• PEG Ratio: -0.87
• Price to Book (P/B): 3.81
• Price to Sales (P/S): 3.24
• P/FCF Ratio: 18.25
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: HK$30.00 ▲(31.81% Upside)

Biocytogen Pharmaceuticals shows strong financial performance with significant profitability and revenue growth, which is the most significant factor in its overall score. Technical indicators suggest a strong upward trend, but caution is warranted due to potential overbought conditions. The high P/E ratio indicates the stock is expensive, which could limit further upside. The absence of earnings call data and corporate events means these factors do not influence the score.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a biotechnology company, engages in the research and development of antibody-based drugs worldwide. The company's pipeline includes 12 core products, among which two products are in Phase II multi-regional clinical trials and two products are in Phase I clinical trials. It focuses on developing drugs in the areas of oncology, autoimmune, inflammatory, metabolic, and other diseases. The company was founded in 2009 and is headquartered in Beijing, China. Beijing Biocytogen Co., Ltd. develops and prepares gene engineered animals to large-scale supply of animal models. It offers preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. The company's products include B-NDG mice, cre mouse models, cre rat models, B-p53 KO mice, B-ApoE KO mice, B-hIL6 mice, B-IL17-EGFP KI mice, B-TGFb1 cKO mice, genome- edited hESC, luciferase reported stable tumor cell lines, B-Pink1 KO rats, B-IL2rg KO rats, B-Cas9D10A cKI rats, B-ApoA4 KO rats, B-LDLR KO rats, B-Prkdc KO rats, B-Rag2 KO rats, B-tdTomato cKI rats, B-ApoE KO rats, B-hTnf mice, and B-hFcgrt (FcRn) mice. Beijing Biocytogen Co., Ltd. also develops antibody research and development platform and provides pharmacology services in the areas of tumor immunity, tumor and autoimmunity, and in vivo and in vitro pharmacology and pharmacology service platform. It also sells its products online. The company was founded in 2008 and is based in Beijing, China with additional locations in Beijing, Haimen, Jiangsu, Shanghai, China; Heidelberg, Germany; and Boston, the United States.

How the Company Makes Money

Biocytogen Pharmaceuticals generates revenue primarily through the development and commercialization of its therapeutic products, which include monoclonal antibodies. The company earns money by partnering with other pharmaceutical firms for drug development, licensing its technologies, and receiving milestone payments as products progress through clinical trials. Additionally, Biocytogen may generate revenue through the sale of its proprietary drug candidates, once they receive regulatory approval. Strategic collaborations with larger pharmaceutical companies also provide financial support, including upfront payments and royalties on future sales, contributing significantly to its earnings.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview

Summary

Biocytogen Pharmaceuticals demonstrates a positive financial trajectory with improvements across income statement, balance sheet, and cash flow metrics. The company has achieved significant profitability and revenue growth, supported by efficient operations and cash management. However, maintaining leverage and ensuring consistent cash flow generation will be crucial for sustaining long-term financial health.

Income Statement

Biocytogen Pharmaceuticals has shown a strong improvement in its income statement metrics over the TTM period. The gross profit margin is robust at 79.5%, indicating effective cost management. The net profit margin has improved significantly to 11.1%, reflecting enhanced profitability. Revenue growth rate is healthy at 9.7%, suggesting positive business momentum. EBIT and EBITDA margins have also improved, indicating operational efficiency. However, historical volatility in profitability remains a concern.

Balance Sheet

The company's balance sheet shows a moderate debt-to-equity ratio of 0.69, which is manageable but slightly elevated compared to previous years. Return on equity has improved to 15.3%, indicating better utilization of shareholder funds. The equity ratio stands at 35.9%, reflecting a stable capital structure. While improvements are evident, the company should continue to monitor its leverage to maintain financial stability.

Cash Flow

Cash flow metrics have shown positive trends, with a strong free cash flow growth rate of 32.1% in the TTM period. The operating cash flow to net income ratio is 0.82, indicating good cash conversion. The free cash flow to net income ratio is 0.88, reflecting efficient cash management. Despite these improvements, the company should focus on sustaining cash flow generation to support future growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.19B	980.45M	716.91M	533.88M	354.56M	253.54M
Gross Profit	946.48M	761.52M	506.03M	391.75M	247.44M	166.99M
EBITDA	382.48M	303.80M	-97.87M	-465.86M	-378.12M	-328.64M
Net Income	132.21M	33.54M	-382.95M	-602.16M	-545.58M	-542.97M
Balance Sheet
Total Assets	2.49B	2.42B	2.45B	2.80B	2.30B	2.33B
Cash, Cash Equivalents and Short-Term Investments	486.84M	381.18M	408.09M	611.27M	566.45M	957.41M
Total Debt	614.18M	570.28M	544.11M	415.28M	89.80M	463.80M
Total Liabilities	1.59B	1.58B	1.66B	1.65B	1.05B	868.28M
Stockholders Equity	892.04M	834.06M	785.89M	1.15B	1.25B	1.45B
Cash Flow
Free Cash Flow	338.66M	174.12M	-203.26M	-543.94M	-564.45M	-531.73M
Operating Cash Flow	385.07M	211.25M	-76.65M	-303.27M	-365.78M	-225.31M
Investing Cash Flow	-188.05M	-137.12M	-100.28M	-153.74M	-84.13M	-188.18M
Financing Cash Flow	-165.85M	-92.03M	-37.82M	587.20M	219.44M	868.44M

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 22.76
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Positive. The current price of 22.76 is below the 20-day moving average (MA) of 24.96, below the 50-day MA of 25.15, and above the 200-day MA of 17.76, indicating a bullish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 62.31 is Neutral, neither overbought nor oversold. The STOCH value of 90.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2315.

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2315	―	HK$11.11B	77.71	16.13%	―	48.38%	―
2171	―	HK$9.98B	―	-42.46%	―	1219.19%	25.15%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1672	―	HK$9.11B	-32.00	-12.74%	―	-76.58%	-4.90%
2162	―	HK$16.92B	―	-8.79%	―	964.40%	65.90%
2157	―	HK$11.52B	-55.06	-21.42%	―	240.05%	-140.09%

Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events

Biocytogen Pharmaceuticals Gains CSRC Approval for A Share Issue

Biocytogen Pharmaceuticals has received approval from the China Securities Regulatory Commission (CSRC) for the registration of its proposed initial public issue of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. This development is a significant step for the company, although the completion of the share issue is contingent on certain conditions. Stakeholders are advised to exercise caution, and further updates will be provided as necessary.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$23.50 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

Biocytogen Pharmaceuticals Gains Approval for A Shares Issuance on Shanghai Sci-Tech Board

Biocytogen Pharmaceuticals has received approval from the Sci-Tech Board of the Shanghai Stock Exchange for its proposed issuance of A Shares. This development marks a significant step in the company’s strategic financial initiatives, potentially enhancing its market presence and offering new opportunities for stakeholders, although the completion of the share issue is subject to certain conditions.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

Biocytogen Pharmaceuticals Advances A Share Offering Plans

Biocytogen Pharmaceuticals has announced the progress of its proposed initial public offering of A Shares on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The company has submitted the necessary prospectus, but the completion of the share issue is subject to certain conditions. Stakeholders are advised to exercise caution as the offering may or may not be completed.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

Biocytogen Pharmaceuticals Reports Strong Financial Turnaround in H1 2025

Biocytogen Pharmaceuticals announced its unaudited consolidated results for the first half of 2025, showing significant financial improvement compared to the same period in 2024. The company reported a 51.3% increase in revenue, reaching RMB 620,963,000, and a gross profit rise of 51.2%. Notably, the company turned a profit of RMB 47,999,000, a significant turnaround from the loss reported in the previous year. These results reflect a strong operational performance and improved market positioning, likely to positively impact stakeholders and enhance the company’s competitive stance in the pharmaceutical industry.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

Biocytogen Pharmaceuticals Enhances Governance with New Nomination Committee

Biocytogen Pharmaceuticals has established a Nomination Committee under its board of directors to regulate the employment and appointment of senior management. This move aims to improve the company’s governance and competitiveness, with the committee responsible for recommending candidates and selection criteria for senior roles, ensuring a majority of independent directors and gender diversity.

The most recent analyst rating on (HK:2315) stock is a Hold with a HK$27.00 price target. To see the full list of analyst forecasts on Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H stock, see the HK:2315 Stock Forecast page.

Biocytogen Pharmaceuticals Schedules Board Meeting to Review Interim Results

Biocytogen Pharmaceuticals has announced a board meeting scheduled for August 28, 2025, to discuss and approve the interim results for the first half of the year and consider the payment of an interim dividend. This meeting is significant as it may impact the company’s financial strategies and shareholder returns, reflecting its operational performance and market positioning.

Biocytogen Pharmaceuticals Reports Strong Revenue Growth and Profit Turnaround in H1 2025

Biocytogen Pharmaceuticals announced preliminary financial data for the first half of 2025, showing a significant revenue increase of approximately 50.1% to 52.5% compared to the previous year, with expected revenues between RMB616.0 million and RMB626.0 million. The company also anticipates a turnaround from a loss to a net profit ranging from RMB42.7 million to RMB52.7 million, driven by strategic R&D investments and expansion in overseas markets, which have bolstered its competitive position and facilitated rapid growth in both domestic and international sectors.